• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

John C. Martin - Articles and news items

Gilead logo

Gilead submits New Drug Application to U.S. FDA for Idelalisib for the treatment of indolent non-Hodgkin’s lymphoma

Industry news, News / 11 September 2013 / Gilead Sciences

Gilead Sciences, Inc. has submitted a NDA to the U.S. FDA for approval of idelalisib, an investigational, targeted, oral inhibitor of PI3K delta, for the treatment of iNHL…

Gilead logo

European Commission approves Stribild®

Industry news, News / 28 May 2013 / Gilead Sciences

Gilead Sciences announced that the European Commission has granted marketing authorization for Stribild®…

Gilead logo

EMA validates Gilead’s marketing application for sofosbuvir for the treatment of hepatitis C

Industry news, News / 21 May 2013 / Gilead Sciences

Gilead Sciences announced that the company’s MAA for sofosbuvir…

Gilead logo

Gilead submits New Drug Application to U.S. FDA for Sofosbuvir

Industry news, News / 8 April 2013 / Gilead Sciences

Sofosbuvir, a once-daily oral nucleotide analogue for the treatment of chronic hepatitis C virus infection…

Gilead logo

European CHMP adopts positive opinion for Stribild®

Industry news, News / 22 March 2013 / Gilead Sciences

Stribild® a once-daily integrase inhibitor-based single tablet regimen for the treatment of HIV-1 infection…

Gilead logo

U.S. FDA approves Gilead’s Stribild™

Industry news, News / 27 August 2012 / Gilead Sciences

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved StribildTM…

Gilead logo

Gilead Sciences announces new collaboration with Indian partners

Industry news, News / 2 August 2012 / Gilead Sciences, Inc.

Gilead Sciences, Inc., together with Mylan Laboratories, Ranbaxy Laboratories Limited and Strides Arcolab, have entered into agreements…

Gilead logo

Gilead receives European marketing authorization for Eviplera®

Industry news, News / 28 November 2011 / Gilead Sciences Inc

Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Eviplera®…

Gilead logo

Gilead Sciences to acquire Pharmasset, Inc. for $11 billion

Industry news, News / 21 November 2011 / Gilead Sciences

Gilead Sciences, Inc., will acquire Pharmasset, Inc., for $137 per share in cash…

Gilead logo

European CHMP adopts positive opinion for Eviplera(R)

Industry news, News / 23 September 2011 / Gilead Sciences, Inc.

CHMP, has adopted a positive opinion on the company’s Marketing Authorisation Application for the once-daily single-tablet regimen, Eviplera(R)…

Gilead logo

U.S. FDA approves Gilead Sciences’ Complera™

Industry news, News / 10 August 2011 / Gilead Sciences Inc

A new complete once-daily, single-tablet regimen for HIV-1 infection in treatment-naïve adults…

Gilead logo

Gilead Sciences’ Kevin Young appointed a Commander of The British Empire

Industry news, News / 13 June 2011 / Gilead Sciences, Inc.

Gilead Sciences, Inc. is pleased to announce that Kevin Young, has been appointed a Commander of The British Empire…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +